| Autor: |
Dumont RA Seiler D Marincek N Brunner P Radojewski P Rochlitz C Müller-Brand J Maecke HR Bri, el M and Walter MA |
| Rok vydání: |
2014 |
| Zdroj: |
Am J Nucl Med Mol Imaging |
| Popis: |
We aimed to explore the effects of (90)Y DOTATOC and (90)Y DOTATOC plus (177)Lu DOTATOC on survival of patients with metastasized gastrinoma. Patients with progressive metastasized gastrinoma were treated with repeated cycles of (90)Y DOTATOC or with cycles alternating between (90)Y DOTATOC and (177)Lu DOTATOC until tumor progression or permanent toxicity. Multivariable Cox regression analyses were used to study predictors of survival. A total of 36 patients were enrolled; 30 patients received (90)Y DOTATOC (median activity per patient 11.8GBq; range: 6.1 62.2GBq) and 6 patients received (90)Y DOTATOC plus (177)Lu DOTATOC (median activity per patient: 14.8GBq; range: 7.4 14.8GBq). Response was found in 26 patients (72.2) including morphological (n=12 33.3) biochemical (n=14 38.9) and/or clinical response (n=6 16.2). A total of 21 patients (58.3) experienced hematotoxicity grade 1/2 while 1 patient (2.8) experienced hematotoxicity grade 3; no grade 4 hematotoxicity occurred. Furthermore 2 patients (5.6) developed grade 4 renal toxicity; no grade 5 renal toxicity occurred. Responders had a significantly longer median survival from time of enrollment than non responders (45.1 months range: 37.1 53.1 months vs. 12.6 months range: 11.0 14.2 hazard ratio: 0.12 (0.027 0.52) p=0.005). Additionally there was a trend towards longer median survival with (90)Y DOTATOC plus (177)Lu DOTATOC as compared to (90)Y DOTATOC alone (60.2 months range: 19.8 100.6 months vs. 27.0 months range: 4.0 50.0 hazard ratio: 0.21 (0.01 3.98) p=0.16). Response to (90)Y DOTATOC and (90)Y DOTATOC plus (177)Lu DOTATOC therapy is associated with a longer survival in patients with metastasized gastrinoma. Both treatment regimens are promising tools for management of progressive gastrinoma. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
